MRPL12 and hepatocellular carcinoma: We found that MRPL12 expression was significantly upregulated and positively associated with worse overall survival in HCC patients (Figure 4G,H), and sorafenib‐treated liver cancer patients whose tumors expressed higher expression of MRPL12 were correlated with lower probability of overall survival (Figure 4I).